Literature DB >> 24439601

Inter-rater reliability of surgical reviews for AREN03B2: a COG renal tumor committee study.

Thomas E Hamilton1, Douglas Barnhart2, Kenneth Gow3, Fernando Ferrer4, Jessica Kandel5, Richard Glick6, Roshni Dasgupta7, Arlene Naranjo8, Ying He8, Eric Gratias9, James Geller10, Elizabeth Mullen11, Peter Ehrlich12.   

Abstract

PURPOSE: The Children's Oncology Group (COG) renal tumor study (AREN03B2) requires real-time central review of radiology, pathology, and the surgical procedure to determine appropriate risk-based therapy. The purpose of this study was to determine the inter-rater reliability of the surgical reviews.
METHODS: Of the first 3200 enrolled AREN03B2 patients, a sample of 100 enriched for blood vessel involvement, spill, rupture, and lymph node involvement was selected for analysis. The surgical assessment was then performed independently by two blinded surgical reviewers and compared to the original assessment, which had been completed by another of the committee surgeons. Variables assessed included surgeon-determined local tumor stage, overall disease stage, type of renal procedure performed, presence of tumor rupture, occurrence of intraoperative tumor spill, blood vessel involvement, presence of peritoneal implants, and interpretation of residual disease. Inter-rater reliability was measured using the Fleiss' Kappa statistic two-sided hypothesis tests (Kappa, p-value).
RESULTS: Local tumor stage correlated in all 3 reviews except in one case (Kappa=0.9775, p<0.001). Similarly, overall disease stage had excellent correlation (0.9422, p<0.001). There was strong correlation for type of renal procedure (0.8357, p<0.001), presence of tumor rupture (0.6858, p<0.001), intraoperative tumor spill (0.6493, p<0.001), and blood vessel involvement (0.6470, p<0.001). Variables that had lower correlation were determination of the presence of peritoneal implants (0.2753, p<0.001) and interpretation of residual disease status (0.5310, p<0.001).
CONCLUSION: The inter-rater reliability of the surgical review is high based on the great consistency in the 3 independent review results. This analysis provides validation and establishes precedent for real-time central surgical review to determine treatment assignment in a risk-based stratagem for multimodal cancer therapy.
© 2014.

Entities:  

Keywords:  Outcomes; Quality assurance; Surgery; Wilms Tumor

Mesh:

Year:  2013        PMID: 24439601      PMCID: PMC4076163          DOI: 10.1016/j.jpedsurg.2013.09.047

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  10 in total

1.  One fish, two fish, we QC fish: controlling data quality among more than 50 organizations over a four-year period.

Authors:  L Riddick; C Simbanin
Journal:  Qual Assur       Date:  2001 Jul-Dec

2.  Quality assessment for Wilms' tumor: a report from the National Wilms' Tumor Study-5.

Authors:  Peter F Ehrlich; Michael L Ritchey; Tomas E Hamilton; Gerald M Haase; San Ou; Norman Breslow; Paul Grundy; Daniel Green; Patricia Norkool; Jennifer Becker; Robert C Shamberger
Journal:  J Pediatr Surg       Date:  2005-01       Impact factor: 2.545

3.  Understanding interobserver agreement: the kappa statistic.

Authors:  Anthony J Viera; Joanne M Garrett
Journal:  Fam Med       Date:  2005-05       Impact factor: 1.756

Review 4.  Pediatric renal tumors: practical updates for the pathologist.

Authors:  Elizabeth J Perlman
Journal:  Pediatr Dev Pathol       Date:  2005-07-14

5.  Lymph node invasion and prognosis in nephroblastoma.

Authors:  B Jereb; M F Tournade; J Lemerle; P A Voûte; J F Delemarre; L Ahstrom; R Flamant; R Gérard-Marchant; B Sandstedt
Journal:  Cancer       Date:  1980-04-01       Impact factor: 6.860

6.  Surgical evaluation of lymph node metastases in Wilms' tumor.

Authors:  H B Othersen; A DeLorimer; E Hrabovsky; P Kelalis; N Breslow; G J D'Angio
Journal:  J Pediatr Surg       Date:  1990-03       Impact factor: 2.545

7.  Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4.

Authors:  R C Shamberger; K A Guthrie; M L Ritchey; G M Haase; J Takashima; J B Beckwith; G J D'Angio; D M Green; N E Breslow
Journal:  Ann Surg       Date:  1999-02       Impact factor: 12.969

8.  The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment.

Authors:  J M Bueno-de-Mesquita; D S A Nuyten; J Wesseling; H van Tinteren; S C Linn; M J van de Vijver
Journal:  Ann Oncol       Date:  2009-07-21       Impact factor: 32.976

9.  Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group.

Authors:  Hans Theodor Eich; Susanne Staar; Axel Gossmann; Katja Hansemann; Roman Skripnitchenko; Martin Kocher; Robert Semrau; Andreas Engert; Andreas Josting; Jeremy Franklin; Barbara Krug; Volker Diehl; Rolf-Peter Müller
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-15       Impact factor: 7.038

10.  Retrospective validation of a new staging system for Wilms' tumor.

Authors:  V T Farewell; G J D'Angio; N Breslow; P Norkool
Journal:  Cancer Clin Trials       Date:  1981
  10 in total
  2 in total

1.  Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534): A Report From the Children's Oncology Group.

Authors:  Peter Ehrlich; Yuen Y Chi; Murali M Chintagumpala; Fred A Hoffer; Elizabeth J Perlman; John A Kalapurakal; Ann Warwick; Robert C Shamberger; Geetika Khanna; Tom E Hamilton; Ken W Gow; Arnold C Paulino; Eric J Gratias; Elizabeth A Mullen; James I Geller; Paul E Grundy; Conrad V Fernandez; Michael L Ritchey; James S Dome
Journal:  Ann Surg       Date:  2017-09       Impact factor: 12.969

Review 2.  Multidisciplinary Treatment Strategies for Wilms Tumor: Recent Advances, Technical Innovations and Future Directions.

Authors:  Till-Martin Theilen; Yannick Braun; Konrad Bochennek; Udo Rolle; Henning C Fiegel; Florian Friedmacher
Journal:  Front Pediatr       Date:  2022-07-14       Impact factor: 3.569

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.